Partnering in Oncology
Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology. Our growing portfolio of partnerships includes a large number of collaborations with academic partners and biotechnology companies and we are actively pursuing new early-science collaborations in our areas of partnering interest.
Our experience
Our innovation strategy in oncology and cancer immunology focuses on developing new treatment options for patients with non-small cell lung cancer (NSCLC), hematological cancer and innovative immune-oncology treatments, with our research resulting in the launch of two products for the treatment of non-small cell lung cancer.
Our oncology pipeline encompasses more than ten clinical stage assets. These are being developed in various cancers and tumor types, including multiple new biological entities and new chemical entities that are currently being investigated in studies involving more than 20,500 patients. We are poised for the next wave of innovation with clinical phase projects involving oncolytic viruses, cancer vaccines and T-cell engagers.
Located in Austria and the USA, our dedicated Oncology research centers are the hubs for our cancer R&D activities where our scientists, working together with our innovation partners, have the ambition to identify and translate the most promising scientific breakthroughs into clinical applications for patients across a wide range of cancers.
Our research focus
Research in oncology and cancer immunology has two major focus areas:
- Cancer cell-directed therapies
- Immune cell-directed therapies.
Our Oncology partnering interests
We are seeking in-licensing and collaborative opportunities at research, pre-clinical and clinical stages, for therapeutic programs in our areas of focus.
Cancer cell-directed therapies including:
- Growth signaling e.g. RTKs, Wnt, Notch, KRAS, MET, MYC
- Regulation of apoptosis
- Epigenetic regulation
- Regulation of protein homeostasis.
Immune cell-directed therapies including:
- Novel immune regulatory checkpoints with a specific interest in those expressed on myeloid lineage cells
- Innate immune stimulatory pathways
- Cancer vaccines and oncolytic viruses
- Novel tumor antigens for coupling to our T cell engager (TCE) platforms
For more information about partnering opportunities in Oncology and Cancer Immunology please contact:
Dr. Ioannis Sapountzis
Phone: +49 6132 77 90626
Email: ioannis.sapountzis@boehringer-ingelheim.com
Dr. Scott M. DeWire
Phone: +1 203 798 4438
Email: scott.dewire@boehringer-ingelheim.com
Dr. Emilio Erazo-Fischer
Phone: +49 6132 77 181604
Email: emilio.erazo-fischer@boehringer-ingelheim.com
-
-
When it comes to outsmarting cancer we are brighter together
Oncology
Innovative research to improve lives for patients with cancer
-
-